• Quoin Pharmaceuticals highlighted positive interim results already released on Aug. 28 from its ongoing Phase 2/3 QRX003 trial in Netherton syndrome.
• The update signals the study is progressing with encouraging early signs, supporting continued development toward a first approved treatment in the indication.
• No future presentation date for additional trial results was disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100830PRIMZONEFULLFEED9824229) on September 10, 2026, and is solely responsible for the information contained therein.